{
    "relation": [
        [
            "",
            "Number of Participants [units: participants]",
            "Age [units: years] Mean (Standard Deviation)",
            "Age, Customized [units: participants]",
            "Between 18 and 29 years",
            "Between 30 and 39 years",
            "Between 40 and 49 years",
            "At least 50 years",
            "Gender [units: participants]",
            "Female",
            "Male",
            "Region of Enrollment [units: participants]",
            "Brazil",
            "Haiti",
            "India",
            "Malawi",
            "Peru",
            "South Africa",
            "Thailand",
            "United States",
            "Zimbabwe",
            "CD4 count, Continuous [1] [units: cells/mm^3] Mean (Standard Deviation)",
            "CD4 count, Categorical [2] [units: participants]",
            "< 50 cells/mm^3",
            "Between 50 and 99 cells/mm^3",
            "Between 100 and 199 cells/mm^3",
            "Between 200 and 249 cells/mm^3",
            "Between 250 and 299 cells/mm^3",
            "Plasma HIV-1 RNA, Continuous [units: log10 copies/mL] Median (Inter-Quartile Range)",
            "Plasma HIV-1 RNA, Categorical [units: participants]",
            "<= 400 copies/mL",
            "Between 400 and 4000 copies/mL",
            "Between 4001 and 40,000 copies/mL",
            "Between 40,001 and 400,000 copies/mL",
            "Between 400,001 and 749,999 copies/mL",
            ">= 750,000 copies/mL",
            "Missing"
        ],
        [
            "ZDV/3TC+EFV",
            "519",
            "35 (9)",
            "",
            "141",
            "244",
            "100",
            "34",
            "",
            "241",
            "278",
            "",
            "79",
            "35",
            "81",
            "74",
            "42",
            "70",
            "32",
            "70",
            "36",
            "163 (85)",
            "",
            "68",
            "70",
            "174",
            "104",
            "103",
            "5.0 (4.6 to 5.4)",
            "",
            "3",
            "22",
            "103",
            "311",
            "45",
            "35",
            "0"
        ],
        [
            "ddI+FTC+ATV",
            "526",
            "35 (8)",
            "",
            "146",
            "221",
            "129",
            "30",
            "",
            "256",
            "270",
            "",
            "76",
            "32",
            "86",
            "74",
            "48",
            "70",
            "33",
            "70",
            "37",
            "167 (83)",
            "",
            "63",
            "77",
            "161",
            "128",
            "97",
            "5.1 (4.5 to 5.5)",
            "",
            "6",
            "19",
            "119",
            "283",
            "58",
            "40",
            "1"
        ],
        [
            "TDF/FTC+EFV",
            "526",
            "35 (9)",
            "",
            "146",
            "225",
            "116",
            "39",
            "",
            "242",
            "284",
            "",
            "76",
            "33",
            "88",
            "73",
            "44",
            "70",
            "35",
            "70",
            "37",
            "155 (81)",
            "",
            "69",
            "82",
            "193",
            "107",
            "75",
            "5.0 (4.5 to 5.5)",
            "",
            "3",
            "14",
            "124",
            "284",
            "55",
            "46",
            "0"
        ],
        [
            "Total",
            "1571",
            "35 (9)",
            "",
            "433",
            "690",
            "345",
            "103",
            "",
            "739",
            "832",
            "",
            "231",
            "100",
            "255",
            "221",
            "134",
            "210",
            "100",
            "210",
            "110",
            "162 (83)",
            "",
            "200",
            "229",
            "528",
            "339",
            "275",
            "5.0 (4.6 to 5.5)",
            "",
            "12",
            "55",
            "346",
            "878",
            "158",
            "121",
            "1"
        ]
    ],
    "pageTitle": "Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00084136",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 10,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987628.47/warc/CC-MAIN-20150728002307-00291-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 845560657,
    "recordOffset": 845544700,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{4211=> On May 23, 2008, Arm B was closed following a planned interim review by the study's independent Data and Safety Monitoring Board (DSMB). The DSMB recommendation was based upon compelling evidence that Arm B had significantly more virologic failure (and therefore was inferior when) compared to Arm A. Participants still receiving Arm B medications were offered alternatives, and all participants continued to be followed.}",
    "textBeforeTable": "Period 1: \u00a0 PI Comparison Participant Flow for 2 periods TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz TDF/FTC+EFV ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine > > On May 23, 2008, Arm B was closed following a planned interim review by the study's independent Data and Safety Monitoring Board (DSMB). The DSMB recommendation was based upon compelling evidence that Arm B had significantly more virologic failure (and therefore was inferior when) compared to Arm A. Participants still receiving Arm B medications were offered alternatives, and all participants continued to be followed. ddI+FTC+ATV ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz ZDV/3TC+EFV Description \u00a0 Reporting Groups HIV-infected, treatment-naive men and women, at least 18 years of age with CD4+ count <300 cells/mm^3. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Study participants were recruited at 43 sites from 9",
    "textAfterTable": "\u00a0 284 \u00a0 \u00a0 832 \u00a0 Region of Enrollment \u00a0 [units:\u00a0participants] \u00a0 \u00a0 \u00a0 \u00a0 Brazil \u00a0 \u00a0 79 \u00a0 \u00a0 76 \u00a0 \u00a0 76 \u00a0 \u00a0 231 \u00a0 Haiti \u00a0 \u00a0 35 \u00a0 \u00a0 32 \u00a0 \u00a0 33 \u00a0 \u00a0 100 \u00a0 India \u00a0 \u00a0 81 \u00a0 \u00a0 86 \u00a0 \u00a0 88 \u00a0 \u00a0 255 \u00a0 Malawi \u00a0 \u00a0 74 \u00a0 \u00a0 74 \u00a0 \u00a0 73 \u00a0 \u00a0 221 \u00a0 Peru \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}